![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SYTL2 |
Gene summary for SYTL2 |
![]() |
Gene information | Species | Human | Gene symbol | SYTL2 | Gene ID | 54843 |
Gene name | synaptotagmin like 2 | |
Gene Alias | CHR11SYT | |
Cytomap | 11q14.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9HCH5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54843 | SYTL2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.02e-03 | 5.01e-01 | 0.3371 |
54843 | SYTL2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 7.35e-04 | 5.63e-01 | 0.343 |
54843 | SYTL2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 4.40e-03 | 4.99e-01 | 0.3329 |
54843 | SYTL2 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.83e-17 | 5.81e-01 | -0.0166 |
54843 | SYTL2 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.34e-22 | 6.71e-01 | -0.0132 |
54843 | SYTL2 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 8.76e-26 | 6.83e-01 | -0.013 |
54843 | SYTL2 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.89e-24 | 7.65e-01 | -0.0121 |
54843 | SYTL2 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.72e-03 | 3.47e-01 | -0.1972 |
54843 | SYTL2 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 8.61e-03 | 4.45e-01 | -0.1433 |
54843 | SYTL2 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 4.26e-10 | 6.57e-01 | -0.1833 |
54843 | SYTL2 | 048752_1579-all-cells | Human | Prostate | BPH | 2.01e-15 | 4.91e-01 | 0.1008 |
54843 | SYTL2 | Dong_P1 | Human | Prostate | Tumor | 6.02e-23 | 2.57e-01 | 0.035 |
54843 | SYTL2 | Dong_P3 | Human | Prostate | Tumor | 2.77e-02 | 1.09e-01 | 0.0278 |
54843 | SYTL2 | Dong_P4 | Human | Prostate | Tumor | 5.65e-05 | 1.67e-01 | 0.0292 |
54843 | SYTL2 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 4.45e-03 | 3.79e-01 | 0.1633 |
54843 | SYTL2 | Pat01-B | Human | Stomach | GC | 3.78e-04 | 6.21e-02 | 0.5754 |
54843 | SYTL2 | Pat02-B | Human | Stomach | GC | 3.60e-16 | 1.55e-01 | 0.0368 |
54843 | SYTL2 | Pat03-B | Human | Stomach | GC | 2.10e-06 | 7.81e-02 | 0.3693 |
54843 | SYTL2 | Pat04-B | Human | Stomach | GC | 4.84e-19 | 3.32e-01 | -0.1483 |
54843 | SYTL2 | Pat05-B | Human | Stomach | GC | 1.50e-11 | 3.95e-01 | -0.0353 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022406 | Colorectum | AD | membrane docking | 31/3918 | 86/18723 | 8.67e-04 | 8.45e-03 | 31 |
GO:0140056 | Colorectum | AD | organelle localization by membrane tethering | 28/3918 | 77/18723 | 1.29e-03 | 1.14e-02 | 28 |
GO:0006887 | Colorectum | AD | exocytosis | 96/3918 | 352/18723 | 2.48e-03 | 1.90e-02 | 96 |
GO:00224061 | Colorectum | SER | membrane docking | 25/2897 | 86/18723 | 9.88e-04 | 1.17e-02 | 25 |
GO:00068871 | Colorectum | SER | exocytosis | 75/2897 | 352/18723 | 2.05e-03 | 2.03e-02 | 75 |
GO:01400561 | Colorectum | SER | organelle localization by membrane tethering | 22/2897 | 77/18723 | 2.46e-03 | 2.32e-02 | 22 |
GO:00224062 | Colorectum | MSS | membrane docking | 28/3467 | 86/18723 | 1.27e-03 | 1.21e-02 | 28 |
GO:01400562 | Colorectum | MSS | organelle localization by membrane tethering | 25/3467 | 77/18723 | 2.34e-03 | 1.91e-02 | 25 |
GO:00224063 | Colorectum | FAP | membrane docking | 22/2622 | 86/18723 | 3.11e-03 | 2.33e-02 | 22 |
GO:01400563 | Colorectum | FAP | organelle localization by membrane tethering | 19/2622 | 77/18723 | 8.67e-03 | 4.98e-02 | 19 |
GO:00224064 | Colorectum | CRC | membrane docking | 20/2078 | 86/18723 | 9.78e-04 | 1.17e-02 | 20 |
GO:01400564 | Colorectum | CRC | organelle localization by membrane tethering | 17/2078 | 77/18723 | 4.05e-03 | 3.35e-02 | 17 |
GO:00068872 | Colorectum | CRC | exocytosis | 55/2078 | 352/18723 | 5.62e-03 | 4.24e-02 | 55 |
GO:00224069 | Esophagus | ESCC | membrane docking | 62/8552 | 86/18723 | 5.93e-07 | 7.79e-06 | 62 |
GO:01400567 | Esophagus | ESCC | organelle localization by membrane tethering | 53/8552 | 77/18723 | 3.33e-05 | 2.74e-04 | 53 |
GO:00482781 | Esophagus | ESCC | vesicle docking | 38/8552 | 59/18723 | 2.86e-03 | 1.21e-02 | 38 |
GO:00224066 | Lung | IAC | membrane docking | 18/2061 | 86/18723 | 5.26e-03 | 3.99e-02 | 18 |
GO:00224067 | Prostate | BPH | membrane docking | 23/3107 | 86/18723 | 1.15e-02 | 4.68e-02 | 23 |
GO:002240612 | Prostate | Tumor | membrane docking | 26/3246 | 86/18723 | 2.29e-03 | 1.29e-02 | 26 |
GO:002240615 | Thyroid | PTC | membrane docking | 48/5968 | 86/18723 | 3.72e-06 | 4.73e-05 | 48 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYTL2 | SNV | Missense_Mutation | rs761827215 | c.1216G>A | p.Glu406Lys | p.E406K | Q9HCH5 | protein_coding | tolerated(0.17) | benign(0.42) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD |
SYTL2 | SNV | Missense_Mutation | novel | c.693N>G | p.Ile231Met | p.I231M | Q9HCH5 | protein_coding | tolerated(0.05) | benign(0.042) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYTL2 | SNV | Missense_Mutation | rs372798070 | c.2095N>A | p.Glu699Lys | p.E699K | Q9HCH5 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYTL2 | SNV | Missense_Mutation | rs183225195 | c.721N>G | p.Met241Val | p.M241V | Q9HCH5 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYTL2 | SNV | Missense_Mutation | novel | c.1483N>G | p.Pro495Ala | p.P495A | Q9HCH5 | protein_coding | deleterious(0.04) | benign(0.045) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SYTL2 | SNV | Missense_Mutation | c.1021N>A | p.Glu341Lys | p.E341K | Q9HCH5 | protein_coding | tolerated(0.21) | benign(0.014) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
SYTL2 | insertion | Frame_Shift_Ins | novel | c.984_985insTACTGCTTTTCCCTGCTAACTAGCCTTGTCTTGAAGGTCTTAC | p.Pro329TyrfsTer27 | p.P329Yfs*27 | Q9HCH5 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SYTL2 | insertion | Nonsense_Mutation | novel | c.719_720insCCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGC | p.Lys240delinsAsnProValSerThrLysAsnThrLysAsnTerProGlyAla | p.K240delinsNPVSTKNTKN*PGA | Q9HCH5 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SYTL2 | insertion | Nonsense_Mutation | novel | c.900_901insTGTTCTTAGGCTTTAAAAGCCCTGAAGGCACTTTCTCCTTCA | p.Ile300_Val301insCysSerTerAlaLeuLysAlaLeuLysAlaLeuSerProSer | p.I300_V301insCS*ALKALKALSPS | Q9HCH5 | protein_coding | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD | ||
SYTL2 | insertion | Frame_Shift_Ins | novel | c.1132_1133insCTGTTCATATCCTTCACCCACTTTTTAATGGGGTTGTT | p.Phe378SerfsTer47 | p.F378Sfs*47 | Q9HCH5 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |